IA
XFOR icon

IFP Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

IFP Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Hold
0
– – – 4740
2021
Q4 		– Sell
-33
Closed -$5K – 3501
2021
Q3 		$5K Buy
+33
New +$5.43K ﹤0.01% 2581

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

IFP Advisors's XFOR Position: Q2 2025 in Review

IFP Advisors held its X4 Pharmaceuticals (XFOR) position steady in Q2 2025 at 0 shares worth $90. The position accounts for ﹤0.01% of the portfolio, ranked #4740.

IFP Advisors first reported a position in XFOR in Q3 2021 and has held it in 1 quarter since. The position peaked at $5K in Q3 2021. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

  • IFP Advisors held 0 shares of X4 Pharmaceuticals worth $90 as of Q2 2025.
  • IFP Advisors left its X4 Pharmaceuticals share count unchanged in Q2 2025.
  • X4 Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2025, its #4740 holding.
  • IFP Advisors first reported a position in X4 Pharmaceuticals in Q3 2021 and has held it in 1 quarter since.
  • IFP Advisors's X4 Pharmaceuticals position peaked at $5K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on IFP Advisors's 13F filing for Q2 2025, filed 24 Jul 2025.